Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onatasertib - Celgene

Drug Profile

Onatasertib - Celgene

Alternative Names: ATG 008; CC 223

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Antengene Corporation; Celgene Corporation
  • Class Antineoplastics; Pyrazines; Pyridines; Small molecules
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer
  • Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
  • No development reported Diffuse large B cell lymphoma; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
  • 25 Sep 2019 Chemical structure information added
  • 20 Jul 2018 STA Pharmaceuticals and Antengene Corporation enter into a strategic partnership for the CMC development and manufacturing of Oncology drugs
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top